All four TRIUMPH Phase 3 trials have reported. The numbers, the dates, the conference presentations and the filing plan, each with its source — updated whenever Lilly or the FDA says something new.
What we know as of 9 October 2026: All four TRIUMPH trials have reported positive topline results, TRIUMPH-1 is published in NEJM, and TRIUMPH-2 was presented in full at EASD on 30 September. Weight loss on 12 mg went up from Phase 2's \u221224.2% at 48 weeks to \u221228.3% at 80 weeks despite the slower Phase 3 titration. Lilly says the data package is complete and plans a Biologics License Application in Q1 2027.
Research use only. Compound Review scores vendors on documentation — laboratory certificates, lot records, pricing and company identity. Nothing on this page is guidance on human or veterinary use, dosing or health outcomes.
Biologics License Application (BLA) to the U.S. FDA planned for the first quarter of 2027; the clinical data package is complete for obesity, obstructive sleep apnea and knee osteoarthritis pain.
A Q1 2027 filing puts a standard-review decision in late 2027 or 2028. No date has been set and Lilly has not announced a priority voucher or breakthrough designation.
Retatrutide is not approved for human use and the trial results on this page are Lilly's. The research-grade market sells it under coded names (GLP-3 R, MA-3RT, PG-3RT and similar); the vendors below are scored on documentation, and every price was read from the vendor's own product page on the date shown.
Research use only. Prices are list prices read from each vendor's product page on the date shown; code prices are list × (1 − the stated discount), not cart-tested. We earn a commission on partner links; the rubric does not read partner status. How we score.
Phase 2 full results presented. 24.2% weight loss at 12 mg confirmed. Lean mass preservation data highlighted.
First comprehensive public presentation of Phase 2 data
Subgroup analysis presented: retatrutide efficacy in T2D subgroup from Phase 2. HbA1c −2.2% at 12 mg.
Established diabetes efficacy case for TRIUMPH-2
Body composition data: ~70% of weight lost was fat mass. Lean mass preservation comparable to tirzepatide.
Addressed key concern about muscle loss with aggressive weight loss
TRIUMPH enrollment update. Slower titration protocol confirmed for Phase 3. No interim efficacy data released.
Confirmed Phase 3 design changes to address GI tolerability
Full TRIUMPH-2 results presented in a dedicated retatrutide symposium: obesity with type 2 diabetes, up to −20.8% at 80 weeks, A1C down up to 1.6 points.
First full presentation of a TRIUMPH trial after the topline releases; the data package Lilly will file in Q1 2027.
Mechanistic data on glucagon receptor component. Thermogenesis and hepatic lipolysis quantified.
Strengthened scientific differentiation vs dual agonists
Based on the Phase 2 data and Phase 3 design changes, here is what the research community expects from TRIUMPH results:
The slower 24-week titration in Phase 3 (vs 12-week in Phase 2) is expected to reduce peak GI adverse events but may also reduce peak weight loss. Analysts project 20–22% average weight loss at the highest dose, vs 24.2% in Phase 2.
The Phase 2 discontinuation rate of 16% due to adverse events was the primary concern. Phase 3's slower titration is specifically designed to address this. Expect discontinuation rates closer to tirzepatide's 7%.
This is the most anticipated data point. If retatrutide shows superior HbA1c reduction and comparable or better weight loss vs tirzepatide, it will establish a clear clinical differentiation. Even non-inferiority would be commercially significant.
Phase 2 showed 82% liver fat reduction — extraordinary for NASH. If TRIUMPH-NASH results are strong, Eli Lilly may pursue NASH as the first FDA indication, similar to how resmetirom (Rezdiffra) received accelerated approval for NASH in 2024.
Third-party tested, batch-verified retatrutide for research purposes.
View Retatrutide at Purgo LabsUse code HEALTH for 20% off
All four TRIUMPH trials have reported positive topline results as of 9 October 2026. TRIUMPH-1 (pivotal obesity trial, 2,339 participants, 80 weeks): −28.3% on 12 mg, −25.9% on 9 mg, −19.0% on 4 mg, vs −2.2% on placebo; 45.3% of the 12 mg arm lost at least 30% of body weight. TRIUMPH-2 (obesity with type 2 diabetes): up to −20.8% with A1C down by up to 1.6 points. TRIUMPH-3 (BMI ≥35 with established cardiovascular disease): up to −22.6%, pre-specified MACE-5 hazard ratio 0.82. TRIUMPH-4 (obesity with knee osteoarthritis): −28.7% at 68 weeks.
TRIUMPH-4 topline came in December 2025, TRIUMPH-1 on 21 May 2026, and TRIUMPH-2 and TRIUMPH-3 on 23 July 2026. TRIUMPH-1 has been published in the New England Journal of Medicine, and the full TRIUMPH-2 results were presented at the EASD annual meeting in Milan on 30 September 2026.
Phase 3 ran longer (80 weeks vs 48) in a far larger population (2,339 in TRIUMPH-1 vs 338 in Phase 2) with a slower dose escalation to limit gastrointestinal events. Weight loss on 12 mg went up, from −24.2% at 48 weeks in Phase 2 to −28.3% at 80 weeks in TRIUMPH-1. Discontinuation for adverse events on 12 mg was 11.3% vs 4.9% on placebo.
There is no head-to-head result. TRIUMPH-1's −28.3% at 80 weeks (12 mg) is numerically above tirzepatide's −20.9% at 72 weeks in SURMOUNT-1 (15 mg), but these are different trials with different populations and durations, so the comparison is indicative only.
Not approved, and no application has been filed as of 9 October 2026. Lilly said on 5 August 2026 that the data package is complete and that it plans to file a Biologics License Application in the first quarter of 2027. That puts a decision in late 2027 or 2028 under a standard review; no priority review has been announced.
Lilly has not announced a brand name. The international non-proprietary name is retatrutide. Lilly used different brand names for tirzepatide by indication (Mounjaro for diabetes, Zepbound for obesity), so a similar split is possible. Research-chemical vendors sell a product labelled retatrutide under names like GLP-3 R or GLP-3 RT; that is not Lilly's drug and is not covered by these trial results.